ログイン

Pain

Pain
71問 • 1年前
  • Tameyra Stefani Al-Suhairy
  • 通報

    問題一覧

  • 1

    Non opioid

  • 2

    Opioid

  • 3

    • Most widely used • Frequently prescribed • Often taken without prescription • More than 50 • Have significant unwanted effects • Newer agents have fewer and less serious adverse action

    Non-steroidal Anti-inflammatory Drugs

  • 4

    • Enzymes that produce PGs 🡪 promote inflammation, pain and fever.

    Cyclooxygenase enzymes

  • 5

    • 3 major types of effect: ◦ Anti-inflammatory effects • Analgesic effect • Antipyretic effect ◦ Inhibition of arachidonate cyclooxygenase thus inhibition of the production of PGs and TXA2

    Non-steroidal Anti-inflammatory Drugs

  • 6

    • Others:  ◦ Inhibit platelet aggregation except selective COX 2 inhibitors • Gastric irritants • Nephrotoxicity • Hepatotoxicity • Hypertensive complications

    Non-steroidal Anti-inflammatory Drugs

  • 7

    NSAIDs: Pharmacokinetics Weak organic acid, except

    Nabumetone

  • 8

    NSAIDs: Pharmacokinetics food does not change their bioavailability, except

    Fenoprofen & Piroxicam

  • 9

    NSAIDs: Pharmacokinetics Highly protein bound (95% - 99%):

    Albumin

  • 10

    (Aspirin, Na salicylate, choline Mg++ trisalicylate, salsalate, diflunisal, sulfasalazine)

    Salicylic acid derivatives

  • 11

    (Indomethacin, Sulindac)

    Para-chlorobenzoic acid derivatives or indoles

  • 12

    (Phenylbutazone, Azapropazone)

    Pyrazolone derivatives

  • 13

    (Ibuprofen, Flurbiprofen, Ketoprofen, Fenoprofen, Naproxen, Oxaprozin)

    Arylpropionic acid

  • 14

     (Mefenamic Acid, Meclofenamic acid)

    Fenamates/Anthranilic acids

  • 15

     (Piroxicam, Tenoxicam)

    Enolic acids/Oxicams

  • 16

    (Diclofenac Sodium, Tolmetin, ketorolac)

    Heteroaryl/Phenylacetic acids

  • 17

    (Nabumetone)

    Alkalones

  • 18

    Aspirin

  • 19

    Pharmacokinetics aspirin

  • 20

    Pharmacodynamics aspirin

  • 21

    Aspirin unwanted effects 4

    Gastric upset, Increases uric acid levels, Glucose intolerance, Salicylism

  • 22

    4 Aspirin drug interactions

    Warfarin, Spirinolactone, Penicillin, ACE inhibitors

  • 23

    2 Aspirin Contraindications

    Hemophilia, Gastric & duodenal ulcers

  • 24

    Diflunisal

  • 25

    Selective COX-2 Inhibitors

  • 26

    Paracetamol unwanted effects

  • 27

    Paracetamol

  • 28

    Corticosteroid drugs

  • 29

    DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDS)

  • 30

    Colchicine

  • 31

    Probenecid & Sulfinpyrazone

  • 32

    • Reduce uric acid synthesis by inhibiting xanthine oxidase and increasing uric acid excretion • Absorption: 80%, oral &  • Terminal serum t1/2 of 1-2 hours • Given o.d. • Indications: chronic tophaceous gout, uric acid urine (24hrs) > 600-700mg, allergic reactions to probenecid & sulfinyrazone, renal impairment, grossly elevated serum uric acid levels • AE: N/V, diarrhea, peripheral neuritis, necrotizing vasculitis, BM depression, aplastic anemia, hepatic toxicity, interstitial nephritis, allergic skin reaction, cataracts

    ALLOPURINOL

  • 33

    Febuxostat

  • 34

    Febuxostat pharmacodynamics

  • 35

    Pegloticase

  • 36

    Adverse effects Pegloticase

  • 37

    Mixed agonist antagonist

  • 38

    Nalbuphine mu

    Antagonist

  • 39

    Nalbuphine kappa

    Agonist

  • 40

    Naltrexone, Naloxone

    Opioid antagonist

  • 41

    Opioid antagonist

  • 42

    Opioid antagonist

  • 43

    Pure agonists

  • 44

    Pure agonists

  • 45

    Pure agonists

  • 46

    Partial/Weak agonist

  • 47

    Partial/Weak agonist

  • 48

    Kappa

  • 49

    Dynorphins

  • 50

    Spinal analgesia

    K1

  • 51

    Supraspinal analgesia

    K3

  • 52

    Delta

  • 53

    associated with supraspinal analgesia

    U1

  • 54

    sub-serves spinal analgesia, respiratory depression, and gastrointestinal actions

    U2

  • 55

    • Morphine and other similar pure agonists have greater affinity (CNS and PNS) • ß-endorphines and enkephalins

    Mu

  • 56

    Opioid Analgesics & Antagonists

  • 57

    Opioid Analgesics & Antagonists

  • 58

    Opioid Analgesics & Antagonists

  • 59

    Opioid Analgesics & Antagonists

  • 60

    Opioid Analgesics & Antagonists

  • 61

    Interleukin-1 Inhibitors

  • 62

    Interleukin-1 Inhibitors

  • 63

    • a fully human anti-IL-1ß monoclonal antibody 🡪 provides rapid and sustained pain relief ◦ Dose: 150mg SC

    Canakinumab

  • 64

    Non-opioid (Nonsteroidal Anti-inflammatory Drugs – NSAIDs) 3

    Non-selective COX inhibitors, Selective COX-2 inhibitors, Selective COX-3 inhibitor

  • 65

    Opioid (Narcotic analgesics) 4

    Pure Agonists, Partial/Weak agonist, Mixed agonist-antagonists, Opioid antagonist

  • 66

    Folic antagonist

    Methotrexate

  • 67

    4.5 days half life Injection site reactions

    Etanercept

  • 68

    IV infusion nausea, headache, sinusitis, rash

    Infliximab

  • 69

    CD20 B lymphocytes

    Rituximab

  • 70

    CD28 to CD80

    Abatacept

  • 71

    15 minutes IV IM

    Parecoxib

  • Sporeformers

    Sporeformers

    Tameyra Stefani Al-Suhairy · 44問 · 1年前

    Sporeformers

    Sporeformers

    44問 • 1年前
    Tameyra Stefani Al-Suhairy

    Spirochetes

    Spirochetes

    Tameyra Stefani Al-Suhairy · 46問 · 1年前

    Spirochetes

    Spirochetes

    46問 • 1年前
    Tameyra Stefani Al-Suhairy

    Subcutaneous, Systemic, Opportunistic Mycoses

    Subcutaneous, Systemic, Opportunistic Mycoses

    Tameyra Stefani Al-Suhairy · 75問 · 1年前

    Subcutaneous, Systemic, Opportunistic Mycoses

    Subcutaneous, Systemic, Opportunistic Mycoses

    75問 • 1年前
    Tameyra Stefani Al-Suhairy

    Mycobacteria

    Mycobacteria

    Tameyra Stefani Al-Suhairy · 46問 · 1年前

    Mycobacteria

    Mycobacteria

    46問 • 1年前
    Tameyra Stefani Al-Suhairy

    Bacterial Classification, morphology, utrastructure

    Bacterial Classification, morphology, utrastructure

    Tameyra Stefani Al-Suhairy · 64問 · 1年前

    Bacterial Classification, morphology, utrastructure

    Bacterial Classification, morphology, utrastructure

    64問 • 1年前
    Tameyra Stefani Al-Suhairy

    HIV

    HIV

    Tameyra Stefani Al-Suhairy · 31問 · 1年前

    HIV

    HIV

    31問 • 1年前
    Tameyra Stefani Al-Suhairy

    CORONA

    CORONA

    Tameyra Stefani Al-Suhairy · 24問 · 1年前

    CORONA

    CORONA

    24問 • 1年前
    Tameyra Stefani Al-Suhairy

    PAPILLO

    PAPILLO

    Tameyra Stefani Al-Suhairy · 15問 · 1年前

    PAPILLO

    PAPILLO

    15問 • 1年前
    Tameyra Stefani Al-Suhairy

    ADENO

    ADENO

    Tameyra Stefani Al-Suhairy · 16問 · 1年前

    ADENO

    ADENO

    16問 • 1年前
    Tameyra Stefani Al-Suhairy

    POX

    POX

    Tameyra Stefani Al-Suhairy · 6問 · 1年前

    POX

    POX

    6問 • 1年前
    Tameyra Stefani Al-Suhairy

    PARVO

    PARVO

    Tameyra Stefani Al-Suhairy · 25問 · 1年前

    PARVO

    PARVO

    25問 • 1年前
    Tameyra Stefani Al-Suhairy

    HEPATOTROPHIC

    HEPATOTROPHIC

    Tameyra Stefani Al-Suhairy · 24問 · 1年前

    HEPATOTROPHIC

    HEPATOTROPHIC

    24問 • 1年前
    Tameyra Stefani Al-Suhairy

    PICORNA

    PICORNA

    Tameyra Stefani Al-Suhairy · 25問 · 1年前

    PICORNA

    PICORNA

    25問 • 1年前
    Tameyra Stefani Al-Suhairy

    RABIES

    RABIES

    Tameyra Stefani Al-Suhairy · 26問 · 1年前

    RABIES

    RABIES

    26問 • 1年前
    Tameyra Stefani Al-Suhairy

    PARAMYXO

    PARAMYXO

    Tameyra Stefani Al-Suhairy · 20問 · 1年前

    PARAMYXO

    PARAMYXO

    20問 • 1年前
    Tameyra Stefani Al-Suhairy

    HERPES

    HERPES

    Tameyra Stefani Al-Suhairy · 40問 · 1年前

    HERPES

    HERPES

    40問 • 1年前
    Tameyra Stefani Al-Suhairy

    ORTHO

    ORTHO

    Tameyra Stefani Al-Suhairy · 7問 · 1年前

    ORTHO

    ORTHO

    7問 • 1年前
    Tameyra Stefani Al-Suhairy

    FLAVI

    FLAVI

    Tameyra Stefani Al-Suhairy · 24問 · 1年前

    FLAVI

    FLAVI

    24問 • 1年前
    Tameyra Stefani Al-Suhairy

    TOGA

    TOGA

    Tameyra Stefani Al-Suhairy · 19問 · 1年前

    TOGA

    TOGA

    19問 • 1年前
    Tameyra Stefani Al-Suhairy

    VIRUS STRUCTURE

    VIRUS STRUCTURE

    Tameyra Stefani Al-Suhairy · 16問 · 1年前

    VIRUS STRUCTURE

    VIRUS STRUCTURE

    16問 • 1年前
    Tameyra Stefani Al-Suhairy

    Normal Flora

    Normal Flora

    Tameyra Stefani Al-Suhairy · 61問 · 1年前

    Normal Flora

    Normal Flora

    61問 • 1年前
    Tameyra Stefani Al-Suhairy

    Bacterial physiology, growth, nutrition

    Bacterial physiology, growth, nutrition

    Tameyra Stefani Al-Suhairy · 63問 · 1年前

    Bacterial physiology, growth, nutrition

    Bacterial physiology, growth, nutrition

    63問 • 1年前
    Tameyra Stefani Al-Suhairy

    Neisseria & Corynebacterium

    Neisseria & Corynebacterium

    Tameyra Stefani Al-Suhairy · 27問 · 1年前

    Neisseria & Corynebacterium

    Neisseria & Corynebacterium

    27問 • 1年前
    Tameyra Stefani Al-Suhairy

    Mycology, superficial,cutaneous mycoses

    Mycology, superficial,cutaneous mycoses

    Tameyra Stefani Al-Suhairy · 31問 · 1年前

    Mycology, superficial,cutaneous mycoses

    Mycology, superficial,cutaneous mycoses

    31問 • 1年前
    Tameyra Stefani Al-Suhairy

    Parasitology (Protozoa, Cestodes, Nematodes, Trematodes)

    Parasitology (Protozoa, Cestodes, Nematodes, Trematodes)

    Tameyra Stefani Al-Suhairy · 10問 · 1年前

    Parasitology (Protozoa, Cestodes, Nematodes, Trematodes)

    Parasitology (Protozoa, Cestodes, Nematodes, Trematodes)

    10問 • 1年前
    Tameyra Stefani Al-Suhairy

    Enterobacteriaceae

    Enterobacteriaceae

    Tameyra Stefani Al-Suhairy · 39問 · 1年前

    Enterobacteriaceae

    Enterobacteriaceae

    39問 • 1年前
    Tameyra Stefani Al-Suhairy

    Chlamydia

    Chlamydia

    Tameyra Stefani Al-Suhairy · 10問 · 1年前

    Chlamydia

    Chlamydia

    10問 • 1年前
    Tameyra Stefani Al-Suhairy

    Staphyloccocus and streptococcus

    Staphyloccocus and streptococcus

    Tameyra Stefani Al-Suhairy · 48問 · 1年前

    Staphyloccocus and streptococcus

    Staphyloccocus and streptococcus

    48問 • 1年前
    Tameyra Stefani Al-Suhairy

    Sterilization and disinfection

    Sterilization and disinfection

    Tameyra Stefani Al-Suhairy · 11問 · 1年前

    Sterilization and disinfection

    Sterilization and disinfection

    11問 • 1年前
    Tameyra Stefani Al-Suhairy

    Bacteria and disease

    Bacteria and disease

    Tameyra Stefani Al-Suhairy · 52問 · 1年前

    Bacteria and disease

    Bacteria and disease

    52問 • 1年前
    Tameyra Stefani Al-Suhairy

    Complement hypersensitivity reactions, immunology, humoral and cell mediated immunity

    Complement hypersensitivity reactions, immunology, humoral and cell mediated immunity

    Tameyra Stefani Al-Suhairy · 99問 · 1年前

    Complement hypersensitivity reactions, immunology, humoral and cell mediated immunity

    Complement hypersensitivity reactions, immunology, humoral and cell mediated immunity

    99問 • 1年前
    Tameyra Stefani Al-Suhairy

    Nematodes

    Nematodes

    Tameyra Stefani Al-Suhairy · 25問 · 1年前

    Nematodes

    Nematodes

    25問 • 1年前
    Tameyra Stefani Al-Suhairy

    Trematodes

    Trematodes

    Tameyra Stefani Al-Suhairy · 23問 · 1年前

    Trematodes

    Trematodes

    23問 • 1年前
    Tameyra Stefani Al-Suhairy

    Cestodes

    Cestodes

    Tameyra Stefani Al-Suhairy · 11問 · 1年前

    Cestodes

    Cestodes

    11問 • 1年前
    Tameyra Stefani Al-Suhairy

    Protozoa

    Protozoa

    Tameyra Stefani Al-Suhairy · 12問 · 1年前

    Protozoa

    Protozoa

    12問 • 1年前
    Tameyra Stefani Al-Suhairy

    Cell injury, cell death, and adaptations

    Cell injury, cell death, and adaptations

    Tameyra Stefani Al-Suhairy · 62問 · 1年前

    Cell injury, cell death, and adaptations

    Cell injury, cell death, and adaptations

    62問 • 1年前
    Tameyra Stefani Al-Suhairy

    GENERAL PRINCIPLES

    GENERAL PRINCIPLES

    Tameyra Stefani Al-Suhairy · 72問 · 1年前

    GENERAL PRINCIPLES

    GENERAL PRINCIPLES

    72問 • 1年前
    Tameyra Stefani Al-Suhairy

    General Principles

    General Principles

    Tameyra Stefani Al-Suhairy · 43問 · 1年前

    General Principles

    General Principles

    43問 • 1年前
    Tameyra Stefani Al-Suhairy

    INTRODUCTION

    INTRODUCTION

    Tameyra Stefani Al-Suhairy · 64問 · 1年前

    INTRODUCTION

    INTRODUCTION

    64問 • 1年前
    Tameyra Stefani Al-Suhairy

    RX WRITING

    RX WRITING

    Tameyra Stefani Al-Suhairy · 33問 · 1年前

    RX WRITING

    RX WRITING

    33問 • 1年前
    Tameyra Stefani Al-Suhairy

    QUIZ CC 1

    QUIZ CC 1

    Tameyra Stefani Al-Suhairy · 10問 · 1年前

    QUIZ CC 1

    QUIZ CC 1

    10問 • 1年前
    Tameyra Stefani Al-Suhairy

    GYPSUM PRODUCTS

    GYPSUM PRODUCTS

    Tameyra Stefani Al-Suhairy · 30問 · 1年前

    GYPSUM PRODUCTS

    GYPSUM PRODUCTS

    30問 • 1年前
    Tameyra Stefani Al-Suhairy

    Genetic Disorders

    Genetic Disorders

    Tameyra Stefani Al-Suhairy · 37問 · 1年前

    Genetic Disorders

    Genetic Disorders

    37問 • 1年前
    Tameyra Stefani Al-Suhairy

    Quiz anesthesia

    Quiz anesthesia

    Tameyra Stefani Al-Suhairy · 10問 · 1年前

    Quiz anesthesia

    Quiz anesthesia

    10問 • 1年前
    Tameyra Stefani Al-Suhairy

    Quiz CNS

    Quiz CNS

    Tameyra Stefani Al-Suhairy · 20問 · 1年前

    Quiz CNS

    Quiz CNS

    20問 • 1年前
    Tameyra Stefani Al-Suhairy

    Quiz ANS

    Quiz ANS

    Tameyra Stefani Al-Suhairy · 20問 · 1年前

    Quiz ANS

    Quiz ANS

    20問 • 1年前
    Tameyra Stefani Al-Suhairy

    Quiz General principles

    Quiz General principles

    Tameyra Stefani Al-Suhairy · 20問 · 1年前

    Quiz General principles

    Quiz General principles

    20問 • 1年前
    Tameyra Stefani Al-Suhairy

    Quiz Rx writing and math calculations

    Quiz Rx writing and math calculations

    Tameyra Stefani Al-Suhairy · 10問 · 1年前

    Quiz Rx writing and math calculations

    Quiz Rx writing and math calculations

    10問 • 1年前
    Tameyra Stefani Al-Suhairy

    INTRO

    INTRO

    Tameyra Stefani Al-Suhairy · 10問 · 1年前

    INTRO

    INTRO

    10問 • 1年前
    Tameyra Stefani Al-Suhairy

    Quiz routes of administration

    Quiz routes of administration

    Tameyra Stefani Al-Suhairy · 10問 · 1年前

    Quiz routes of administration

    Quiz routes of administration

    10問 • 1年前
    Tameyra Stefani Al-Suhairy

    HEMODYNAMICS, COAGULATION CASCADES, THROMBOSIS SHOCK PATHOLOGY

    HEMODYNAMICS, COAGULATION CASCADES, THROMBOSIS SHOCK PATHOLOGY

    Tameyra Stefani Al-Suhairy · 12問 · 1年前

    HEMODYNAMICS, COAGULATION CASCADES, THROMBOSIS SHOCK PATHOLOGY

    HEMODYNAMICS, COAGULATION CASCADES, THROMBOSIS SHOCK PATHOLOGY

    12問 • 1年前
    Tameyra Stefani Al-Suhairy

    QUIZ CC 2

    QUIZ CC 2

    Tameyra Stefani Al-Suhairy · 10問 · 1年前

    QUIZ CC 2

    QUIZ CC 2

    10問 • 1年前
    Tameyra Stefani Al-Suhairy

    Impression materials

    Impression materials

    Tameyra Stefani Al-Suhairy · 78問 · 1年前

    Impression materials

    Impression materials

    78問 • 1年前
    Tameyra Stefani Al-Suhairy

    Quiz anesthesia LECTURE

    Quiz anesthesia LECTURE

    Tameyra Stefani Al-Suhairy · 20問 · 1年前

    Quiz anesthesia LECTURE

    Quiz anesthesia LECTURE

    20問 • 1年前
    Tameyra Stefani Al-Suhairy

    ANESTHESIA

    ANESTHESIA

    Tameyra Stefani Al-Suhairy · 66問 · 1年前

    ANESTHESIA

    ANESTHESIA

    66問 • 1年前
    Tameyra Stefani Al-Suhairy

    QUIZ cell injury cell death and adaptations

    QUIZ cell injury cell death and adaptations

    Tameyra Stefani Al-Suhairy · 8問 · 1年前

    QUIZ cell injury cell death and adaptations

    QUIZ cell injury cell death and adaptations

    8問 • 1年前
    Tameyra Stefani Al-Suhairy

    QUIZ genetic disorders

    QUIZ genetic disorders

    Tameyra Stefani Al-Suhairy · 10問 · 1年前

    QUIZ genetic disorders

    QUIZ genetic disorders

    10問 • 1年前
    Tameyra Stefani Al-Suhairy

    QUIZ HEMODYNAMICS, COAGULATION CASCADES, THROMBOSIS SHOCK PATHOLOGY

    QUIZ HEMODYNAMICS, COAGULATION CASCADES, THROMBOSIS SHOCK PATHOLOGY

    Tameyra Stefani Al-Suhairy · 10問 · 1年前

    QUIZ HEMODYNAMICS, COAGULATION CASCADES, THROMBOSIS SHOCK PATHOLOGY

    QUIZ HEMODYNAMICS, COAGULATION CASCADES, THROMBOSIS SHOCK PATHOLOGY

    10問 • 1年前
    Tameyra Stefani Al-Suhairy

    Enamel

    Enamel

    Tameyra Stefani Al-Suhairy · 100問 · 1年前

    Enamel

    Enamel

    100問 • 1年前
    Tameyra Stefani Al-Suhairy

    Enamel PART 2

    Enamel PART 2

    Tameyra Stefani Al-Suhairy · 9問 · 1年前

    Enamel PART 2

    Enamel PART 2

    9問 • 1年前
    Tameyra Stefani Al-Suhairy

    Dentin

    Dentin

    Tameyra Stefani Al-Suhairy · 78問 · 1年前

    Dentin

    Dentin

    78問 • 1年前
    Tameyra Stefani Al-Suhairy

    QUIZ Dentin Pulp

    QUIZ Dentin Pulp

    Tameyra Stefani Al-Suhairy · 10問 · 1年前

    QUIZ Dentin Pulp

    QUIZ Dentin Pulp

    10問 • 1年前
    Tameyra Stefani Al-Suhairy

    Pulp

    Pulp

    Tameyra Stefani Al-Suhairy · 70問 · 1年前

    Pulp

    Pulp

    70問 • 1年前
    Tameyra Stefani Al-Suhairy

    Physical exam history taking ppt

    Physical exam history taking ppt

    Tameyra Stefani Al-Suhairy · 60問 · 1年前

    Physical exam history taking ppt

    Physical exam history taking ppt

    60問 • 1年前
    Tameyra Stefani Al-Suhairy

    Saliva and salivary glands

    Saliva and salivary glands

    Tameyra Stefani Al-Suhairy · 76問 · 1年前

    Saliva and salivary glands

    Saliva and salivary glands

    76問 • 1年前
    Tameyra Stefani Al-Suhairy

    INTRO PPT

    INTRO PPT

    Tameyra Stefani Al-Suhairy · 77問 · 1年前

    INTRO PPT

    INTRO PPT

    77問 • 1年前
    Tameyra Stefani Al-Suhairy

    Pulp PART 2

    Pulp PART 2

    Tameyra Stefani Al-Suhairy · 36問 · 1年前

    Pulp PART 2

    Pulp PART 2

    36問 • 1年前
    Tameyra Stefani Al-Suhairy

    INTRO

    INTRO

    Tameyra Stefani Al-Suhairy · 11問 · 1年前

    INTRO

    INTRO

    11問 • 1年前
    Tameyra Stefani Al-Suhairy

    PERIODONTIUM

    PERIODONTIUM

    Tameyra Stefani Al-Suhairy · 100問 · 1年前

    PERIODONTIUM

    PERIODONTIUM

    100問 • 1年前
    Tameyra Stefani Al-Suhairy

    PERIODONTIUM PART 2

    PERIODONTIUM PART 2

    Tameyra Stefani Al-Suhairy · 67問 · 1年前

    PERIODONTIUM PART 2

    PERIODONTIUM PART 2

    67問 • 1年前
    Tameyra Stefani Al-Suhairy

    Quiz pulp

    Quiz pulp

    Tameyra Stefani Al-Suhairy · 12問 · 1年前

    Quiz pulp

    Quiz pulp

    12問 • 1年前
    Tameyra Stefani Al-Suhairy

    SALIVA

    SALIVA

    Tameyra Stefani Al-Suhairy · 17問 · 1年前

    SALIVA

    SALIVA

    17問 • 1年前
    Tameyra Stefani Al-Suhairy

    Inflammation and repair LECTURE

    Inflammation and repair LECTURE

    Tameyra Stefani Al-Suhairy · 35問 · 1年前

    Inflammation and repair LECTURE

    Inflammation and repair LECTURE

    35問 • 1年前
    Tameyra Stefani Al-Suhairy

    Inflammation and repair part 2

    Inflammation and repair part 2

    Tameyra Stefani Al-Suhairy · 12問 · 1年前

    Inflammation and repair part 2

    Inflammation and repair part 2

    12問 • 1年前
    Tameyra Stefani Al-Suhairy

    WEEK 1 IC

    WEEK 1 IC

    Tameyra Stefani Al-Suhairy · 49問 · 1年前

    WEEK 1 IC

    WEEK 1 IC

    49問 • 1年前
    Tameyra Stefani Al-Suhairy

    WEEK 2 HEPA

    WEEK 2 HEPA

    Tameyra Stefani Al-Suhairy · 34問 · 1年前

    WEEK 2 HEPA

    WEEK 2 HEPA

    34問 • 1年前
    Tameyra Stefani Al-Suhairy

    WEEK 3 HIV

    WEEK 3 HIV

    Tameyra Stefani Al-Suhairy · 27問 · 1年前

    WEEK 3 HIV

    WEEK 3 HIV

    27問 • 1年前
    Tameyra Stefani Al-Suhairy

    WEEK 4 TB

    WEEK 4 TB

    Tameyra Stefani Al-Suhairy · 30問 · 1年前

    WEEK 4 TB

    WEEK 4 TB

    30問 • 1年前
    Tameyra Stefani Al-Suhairy

    infectious disease

    infectious disease

    Tameyra Stefani Al-Suhairy · 10問 · 1年前

    infectious disease

    infectious disease

    10問 • 1年前
    Tameyra Stefani Al-Suhairy

    anti tb week 1

    anti tb week 1

    Tameyra Stefani Al-Suhairy · 57問 · 1年前

    anti tb week 1

    anti tb week 1

    57問 • 1年前
    Tameyra Stefani Al-Suhairy

    Elastomeric (Rubber) Impression Materials

    Elastomeric (Rubber) Impression Materials

    Tameyra Stefani Al-Suhairy · 67問 · 1年前

    Elastomeric (Rubber) Impression Materials

    Elastomeric (Rubber) Impression Materials

    67問 • 1年前
    Tameyra Stefani Al-Suhairy

    antiseptics and disinfectants

    antiseptics and disinfectants

    Tameyra Stefani Al-Suhairy · 45問 · 1年前

    antiseptics and disinfectants

    antiseptics and disinfectants

    45問 • 1年前
    Tameyra Stefani Al-Suhairy

    Olfaction

    Olfaction

    Tameyra Stefani Al-Suhairy · 46問 · 1年前

    Olfaction

    Olfaction

    46問 • 1年前
    Tameyra Stefani Al-Suhairy

    Taste

    Taste

    Tameyra Stefani Al-Suhairy · 31問 · 1年前

    Taste

    Taste

    31問 • 1年前
    Tameyra Stefani Al-Suhairy

    Mastication and deglutition

    Mastication and deglutition

    Tameyra Stefani Al-Suhairy · 19問 · 1年前

    Mastication and deglutition

    Mastication and deglutition

    19問 • 1年前
    Tameyra Stefani Al-Suhairy

    Tactile sensation

    Tactile sensation

    Tameyra Stefani Al-Suhairy · 32問 · 1年前

    Tactile sensation

    Tactile sensation

    32問 • 1年前
    Tameyra Stefani Al-Suhairy

    Respiratory

    Respiratory

    Tameyra Stefani Al-Suhairy · 61問 · 1年前

    Respiratory

    Respiratory

    61問 • 1年前
    Tameyra Stefani Al-Suhairy

    Susceptible host

    Susceptible host

    Tameyra Stefani Al-Suhairy · 73問 · 1年前

    Susceptible host

    Susceptible host

    73問 • 1年前
    Tameyra Stefani Al-Suhairy

    Biofilm

    Biofilm

    Tameyra Stefani Al-Suhairy · 46問 · 1年前

    Biofilm

    Biofilm

    46問 • 1年前
    Tameyra Stefani Al-Suhairy

    Dental caries

    Dental caries

    Tameyra Stefani Al-Suhairy · 67問 · 1年前

    Dental caries

    Dental caries

    67問 • 1年前
    Tameyra Stefani Al-Suhairy

    Substrate

    Substrate

    Tameyra Stefani Al-Suhairy · 36問 · 1年前

    Substrate

    Substrate

    36問 • 1年前
    Tameyra Stefani Al-Suhairy

    infectious disease lec

    infectious disease lec

    Tameyra Stefani Al-Suhairy · 48問 · 1年前

    infectious disease lec

    infectious disease lec

    48問 • 1年前
    Tameyra Stefani Al-Suhairy

    問題一覧

  • 1

    Non opioid

  • 2

    Opioid

  • 3

    • Most widely used • Frequently prescribed • Often taken without prescription • More than 50 • Have significant unwanted effects • Newer agents have fewer and less serious adverse action

    Non-steroidal Anti-inflammatory Drugs

  • 4

    • Enzymes that produce PGs 🡪 promote inflammation, pain and fever.

    Cyclooxygenase enzymes

  • 5

    • 3 major types of effect: ◦ Anti-inflammatory effects • Analgesic effect • Antipyretic effect ◦ Inhibition of arachidonate cyclooxygenase thus inhibition of the production of PGs and TXA2

    Non-steroidal Anti-inflammatory Drugs

  • 6

    • Others:  ◦ Inhibit platelet aggregation except selective COX 2 inhibitors • Gastric irritants • Nephrotoxicity • Hepatotoxicity • Hypertensive complications

    Non-steroidal Anti-inflammatory Drugs

  • 7

    NSAIDs: Pharmacokinetics Weak organic acid, except

    Nabumetone

  • 8

    NSAIDs: Pharmacokinetics food does not change their bioavailability, except

    Fenoprofen & Piroxicam

  • 9

    NSAIDs: Pharmacokinetics Highly protein bound (95% - 99%):

    Albumin

  • 10

    (Aspirin, Na salicylate, choline Mg++ trisalicylate, salsalate, diflunisal, sulfasalazine)

    Salicylic acid derivatives

  • 11

    (Indomethacin, Sulindac)

    Para-chlorobenzoic acid derivatives or indoles

  • 12

    (Phenylbutazone, Azapropazone)

    Pyrazolone derivatives

  • 13

    (Ibuprofen, Flurbiprofen, Ketoprofen, Fenoprofen, Naproxen, Oxaprozin)

    Arylpropionic acid

  • 14

     (Mefenamic Acid, Meclofenamic acid)

    Fenamates/Anthranilic acids

  • 15

     (Piroxicam, Tenoxicam)

    Enolic acids/Oxicams

  • 16

    (Diclofenac Sodium, Tolmetin, ketorolac)

    Heteroaryl/Phenylacetic acids

  • 17

    (Nabumetone)

    Alkalones

  • 18

    Aspirin

  • 19

    Pharmacokinetics aspirin

  • 20

    Pharmacodynamics aspirin

  • 21

    Aspirin unwanted effects 4

    Gastric upset, Increases uric acid levels, Glucose intolerance, Salicylism

  • 22

    4 Aspirin drug interactions

    Warfarin, Spirinolactone, Penicillin, ACE inhibitors

  • 23

    2 Aspirin Contraindications

    Hemophilia, Gastric & duodenal ulcers

  • 24

    Diflunisal

  • 25

    Selective COX-2 Inhibitors

  • 26

    Paracetamol unwanted effects

  • 27

    Paracetamol

  • 28

    Corticosteroid drugs

  • 29

    DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDS)

  • 30

    Colchicine

  • 31

    Probenecid & Sulfinpyrazone

  • 32

    • Reduce uric acid synthesis by inhibiting xanthine oxidase and increasing uric acid excretion • Absorption: 80%, oral &  • Terminal serum t1/2 of 1-2 hours • Given o.d. • Indications: chronic tophaceous gout, uric acid urine (24hrs) > 600-700mg, allergic reactions to probenecid & sulfinyrazone, renal impairment, grossly elevated serum uric acid levels • AE: N/V, diarrhea, peripheral neuritis, necrotizing vasculitis, BM depression, aplastic anemia, hepatic toxicity, interstitial nephritis, allergic skin reaction, cataracts

    ALLOPURINOL

  • 33

    Febuxostat

  • 34

    Febuxostat pharmacodynamics

  • 35

    Pegloticase

  • 36

    Adverse effects Pegloticase

  • 37

    Mixed agonist antagonist

  • 38

    Nalbuphine mu

    Antagonist

  • 39

    Nalbuphine kappa

    Agonist

  • 40

    Naltrexone, Naloxone

    Opioid antagonist

  • 41

    Opioid antagonist

  • 42

    Opioid antagonist

  • 43

    Pure agonists

  • 44

    Pure agonists

  • 45

    Pure agonists

  • 46

    Partial/Weak agonist

  • 47

    Partial/Weak agonist

  • 48

    Kappa

  • 49

    Dynorphins

  • 50

    Spinal analgesia

    K1

  • 51

    Supraspinal analgesia

    K3

  • 52

    Delta

  • 53

    associated with supraspinal analgesia

    U1

  • 54

    sub-serves spinal analgesia, respiratory depression, and gastrointestinal actions

    U2

  • 55

    • Morphine and other similar pure agonists have greater affinity (CNS and PNS) • ß-endorphines and enkephalins

    Mu

  • 56

    Opioid Analgesics & Antagonists

  • 57

    Opioid Analgesics & Antagonists

  • 58

    Opioid Analgesics & Antagonists

  • 59

    Opioid Analgesics & Antagonists

  • 60

    Opioid Analgesics & Antagonists

  • 61

    Interleukin-1 Inhibitors

  • 62

    Interleukin-1 Inhibitors

  • 63

    • a fully human anti-IL-1ß monoclonal antibody 🡪 provides rapid and sustained pain relief ◦ Dose: 150mg SC

    Canakinumab

  • 64

    Non-opioid (Nonsteroidal Anti-inflammatory Drugs – NSAIDs) 3

    Non-selective COX inhibitors, Selective COX-2 inhibitors, Selective COX-3 inhibitor

  • 65

    Opioid (Narcotic analgesics) 4

    Pure Agonists, Partial/Weak agonist, Mixed agonist-antagonists, Opioid antagonist

  • 66

    Folic antagonist

    Methotrexate

  • 67

    4.5 days half life Injection site reactions

    Etanercept

  • 68

    IV infusion nausea, headache, sinusitis, rash

    Infliximab

  • 69

    CD20 B lymphocytes

    Rituximab

  • 70

    CD28 to CD80

    Abatacept

  • 71

    15 minutes IV IM

    Parecoxib